Brian Rini, MD, and Hans Hammers, MD, PhD, discuss the evolution of management for advanced renal cell carcinoma (RCC), noting the role of biomarkers and its use in practice.
Leading oncologists discuss advanced treatment options for patients with progressing renal cell carcinoma (RCC), focusing on the promising results from LITESPARK-005 and treatment sequencing strategies.
Expert oncologists discuss the nuances of managing toxicities associated with Cabozantinib and Nivolumab combination therapy for advanced renal cell carcinoma (RCC).
Final outcomes from the phase 1b/2 Study 111/KEYNOTE-146 trial, evaluating treatment with lenvatinib and pembrolizumab in patients with advanced renal cell carcinoma, has sparked interest in the use of this combination.
A comprehensive discussion on VEGF-TKI-based combinations and immune checkpoint inhibitor combinations in the treatment of renal cell carcinoma, featuring key clinical trial results and treatment strategies.